Substance / Medication

Phenazone

Overview

Active Ingredient
antipyrine
RxNorm CUI
1001

Indications

Acute Otitis media of various etiologies -prompt relief of pain and reduction of inflammation in the congestive and serous stages. -adjuvant therapy during systemic antibiotic administration for resolution of the infection. Because of the close anatomical relationship of the eustachian tube to the nasal cavity, otitis media is a frequent problem, especially in children in whom the tube is shorter, wider, and more horizontal than in adults. Removal of Cerumen -facilitates the removal of excessive

Labeler: Rebel Distributors CorpUpdated: 2011-01-17T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

The product is contraindicated in any person with hypersensitivity to any of the components or substances related to them.This product is contraindicated in the presence of spontaneous perforation of the tympanic membrane or discharge.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Therapeutic properties and tolerance of procaine and phenazone containing ear drops in infants and very young children.
Adam Dieter, Federspil Pierre, Lukes Martin et al. · Arzneimittelforschung · 2009
PMID: 19998578RCT
Validation of an HPLC method for the simultaneous determination of diminazene diaceturate and phenazone in injectable veterinary granules and bulk powders.
Kassaye Lantider, Hymete Ariaya, Bekhit Adnan Ahmed et al. · Pak J Pharm Sci · 2012
PMID: 22186338Observational
Effect of ozagrel, a selective thromboxane A2-synthetase inhibitor, on cerebral infarction in rats. Comparative study with norphenazone, a free-radical scavenger.
Imamura Takahiro, Kiguchi Sumiyoshi, Kobayashi Kumi et al. · Arzneimittelforschung · 2003
PMID: 14650360Observational
Biological and metabolic study of naproxen-propyphenazone mutual prodrug.
Sheha Mahmoud, Khedr Alaa, Elsherief Hosny · Eur J Pharm Sci · 2002
PMID: 12393139Observational
Hair analysis to monitor abuse of analgesic combinations containing butalbital and propyphenazone.
Ferrari Anna, Tiraferri Ilaria, Palazzoli Federica et al. · J Pharm Biomed Anal · 2015
PMID: 26319751Case Report
A fatal intoxication with phenazone (antipyrine).
Karinen Ritva, Høiseth Gudrun, Svendsen Kristin Opsal et al. · Forensic Sci Int · 2015
PMID: 25631541Case Report
Acute inferior myocardial infarction with low atrial rhythm due to propyphenazone: Kounis syndrome.
Akyel Ahmet, Alsancak Yakup, Yayla Çağrı et al. · Int J Cardiol · 2011
PMID: 20541820Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Phenazone (substance)
SNOMED CT
55486005
UMLS CUI
C0003420
RxNorm CUI
1001
Labeler
Rebel Distributors Corp

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.